Skip to content

Palvella Therapeutics, Inc.

PVLA· NasdaqCore metricsCIK 1583648

Pharmaceutical preparations551 peers

Last sale
Nov 12, 2026 · -6.56%
Market cap
$2.24B
14.62M shares
Filings
819
$0.00
Q3 2024+65.3% FY23 yoy
-$24.64M
Q3 2026N/M FY25 yoy
-$22.73M
Q3 2026N/M FY25 yoy
-$5.45M
Q3 2024derivedN/M FY23 yoy
-$1.70
Q3 2026N/M FY25 yoy
$193.30M
Q3 2026−30.6% FY25 yoy
$2.24B
—
—
11.3×
—
—

FY2025 figures · derived

Price

$153.02+97.33%+$75.48past year
Nov 12, 2026 · IEX last sale
Figure
Range
IEX last saleClose of recordAs traded

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Revenue

$42.81MFY 2023
$43.65M0FY 2013FY 2018FY 2023
PeriodEndedValueKindSource trail
FY 20232023-12-31$42,810,000reported
FY 20222022-12-31$25,902,000reported
FY 20212021-12-31$31,418,000reported
FY 20202020-12-31$29,323,000reported
FY 20192019-12-31$43,646,000 revisedreported
FY 20182018-12-31$27,248,000 revisedreported
FY 20172017-12-31$25,275,000reported
FY 20162016-12-31$5,831,000reported
FY 20152015-12-31$2,931,931reported
FY 20142014-12-31$5,365,054reported
FY 20132013-12-31$12,427,292reported

Segments

Products
Revenue by Products, FY2019 to FY2019FY2019Customer revenue · FY2019 · $32.07MCollaboration revenue · FY2019 · $14.21M
LineFY2019ShareChange
Customer revenue$32.07M69%—
Collaboration revenue$14.21M31%—
Total$46.28M

From the 10-K filed Mar 31, 2021PVLA

Pharmaceutical preparations

Palvella Therapeutics, Inc. is the 87th largest of the 552 covered companies the SEC files under this code, by market cap. SIC 2834

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in market cap first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

Palvella Therapeutics, Inc. · CIK 1583648 · Engraved from SEC EDGAR